FDA Grants New Indication to Taltz for Certain Axial Spondyloarthritis

By PPN News Staff

The FDA granted a new indication to ixekizumab (Taltz, Eli Lilly) injection for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation.